NVS Jan 2025 100.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:31AM EST. Market open.
| Previous close | 8.00 |
| Open | 8.00 |
| Bid | 5.90 |
| Ask | 10.00 |
| Strike | 100.00 |
| Expiry date | 2025-01-17 |
| Day's range | 8.00 - 8.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 68 |
ZacksCAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
ZacksNovartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy
Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.
- Financial Times
Novartis: CEO needs to convince over long-term prospects
It is tempting to celebrate big milestones. Novartis chief Vas Narasimhan can be forgiven for doing so. His focus is on higher-margin, innovative drugs. The Swiss group is a cleaner proposition after spinning off its generics business Sandoz in October.
© 2023 Yahoo. All rights reserved.